Blockchain Registration Transaction Record

NeuroThera and Clearmind File Patent for Novel Depression Therapy

NeuroThera Labs and Clearmind Medicine file a patent for a novel MEAI-PEA combination therapy to treat major depressive disorder, offering a non-hallucinogenic neuroplastogen alternative to traditional antidepressants.

This development is crucial as it introduces a potential breakthrough in treating major depressive disorder, a condition affecting over 332 million people globally. The MEAI-PEA combination therapy offers a non-hallucinogenic neuroplastogen approach that could provide a safer, more accessible, and affordable alternative to existing antidepressants like SSRIs. By targeting neuroplasticity without the risks associated with hallucinogens, it addresses common limitations of current treatments, such as side effects and variable efficacy. This innovation could significantly improve patient outcomes, reduce healthcare burdens, and advance mental health care, making it relevant for individuals, families, and the broader medical community.